Navigation Links
UCLA scientists find male gene in brain area targeted by Parkinson's

UCLA scientists have discovered that a sex gene responsible for making embryos male and forming the testes is also produced by the brain region targeted by Parkinson's disease. Published in the Feb. 21 edition of Current Biology, the new research may explain why more men than women develop the degenerative disorder, which afflicts roughly 1 million Americans.

"Men are 1.5 times more likely to develop Parkinson's disease than women," said Dr. Eric Vilain, associate professor of human genetics at the David Geffen School of Medicine at UCLA. "Our findings may offer new clues to how the disorder affects men and women differently, and shed light on why men are more susceptible to the disease."

In 1990, British researchers identified SRY as the gene that determines gender and makes embryos male. Located on the male sex chromosome, SRY manufactures a protein that is secreted by cells in the testes.

Now, in an unexpected discovery, Vilain's team became the first to trace the SRY protein to a region of the brain called the substantia nigra, which deteriorates in Parkinson's disease.

Parkinson's disease occurs when cells in the substantia nigra begin to malfunction and die. These brain cells produce a neurotransmitter called dopamine that communicates with the brain areas controlling movement and coordination.

As the cells die off, they produce less dopamine. This slows the delivery of messages from the brain to the rest of the body, leaving the person unable to initiate or control their physical movements. The condition eventually leads to paralysis.

"For the first time, we've discovered that the brain cells that produce dopamine depend upon a sex-specific gene to function properly," Vilain said. "We've also shown that SRY plays a central role not just in the male genitals, but also in regulating the brain."

Vilain's lab used a rat model to study the effect of SRY on the brain. When the researchers lowered the level of SRY in the substantia nigra, they saw a corresponding drop in an enzyme called tyrosine hydroxylase (TH), which plays a key role in the brain's production of dopamine.

In a surprise finding, the drop in TH occurred only in the male rats. The female rats remained unaffected.

"When we reduced SRY levels in the rats' brains, the male animals began experiencing the movement problems caused by insufficient dopamine," Vilain said. "Low levels of SRY triggered Parkinson's symptoms in the male rats, cutting their physical agility by half in a week.

"Initially, the rat could walk 14 steps in 10 seconds," he noted. "After we lowered the SRY levels in its brain, the rat could only manage seven steps in the same amount of time."

Vilain believes that variations in SRY levels may be linked to the onset of Parkinson's and could offer insights into who is at risk for the disease.

"SRY may serve as a protective agent against Parkinson's," he said. "Men who contract the disease may have lower levels of the gene in the brain."

Because SRY is found only in males, Vilain thinks women must possess another physiological mechanism that protects dopamine-producing cells in the substantia nigra.

"We suspect that estrogens in women could play the same role as SRY in protecting the female brain from Parkinson's disease," he said. "Our lab is currently studying this hypothesis in an animal model."

Sex differences in other dopamine-linked disorders, such as schizophrenia or addiction, may also be explained by the SRY gene, Vilain said.

"It's possible that dopamine-related disorders that reveal dramatic differences in severity and rates in the genders could depend on the SRY levels in the brain," he said.


'"/>

Source:University of California - Los Angeles


Related biology news :

1. Wisconsin scientists grow critical nerve cells
2. UCSB scientists probe sea floor venting to gain understanding of early life on Earth
3. UAB scientists discover the origin of a mysterious physical force
4. Fox Chase Cancer Center scientists identify immune-system mutation
5. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
6. U-M scientists find genes that control growth of common skin cancer
7. UCLA scientists transform HIV into cancer-seeking missile
8. RNA project to create language for scientists worldwide
9. Carnegie Mellon scientists develop tool that uses MRI to visualize gene expression in living animals
10. To control germs, scientists deploy tiny agents provocateurs
11. Leprosy microbes lead scientists to immune discovery
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology: